Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23887259 | 1.00 | MAPK14 (0.44) | MAPK14KDM1ARAB9ASMN1; SMN2TDP1 | |
| SCHEMBL30782654 | 0.85 | KDM1A (0.47) | MAPK14KDM1ARAB9ASMN1; SMN2TDP1 | |
| SCHEMBL319757 | 0.85 | KDM1A (0.47) | MAPK14KDM1ARAB9ASMN1; SMN2TDP1 | |
| SCHEMBL31166800 | 0.82 | KDM1A (0.44) | KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL30338101 | 0.81 | KDM1A (0.47) | MAPK14KDM1ARAB9ASMN1; SMN2TDP1 | |
| SCHEMBL23886907 | 0.81 | KDM1A (0.47) | MAPK14KDM1ARAB9ASMN1; SMN2TDP1 | |
| SCHEMBL5107039 | 0.81 | SMN1; SMN2 (0.47) | KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL20607764 | 0.79 | MAPK14 (0.43) | MAPK14KDM1ATDP1L3MBTL1MAPT | |
| SCHEMBL20607861 | 0.79 | MAPK14 (0.47) | MAPK14KDM1ATDP1L3MBTL1MAPT | |
| SCHEMBL8613438 | 0.79 | KDM1A (0.43) | KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| CN-115916749-A | Substituted 5-hydroxyindole compounds as alpha-1 antitrypsin modulators | 弗特克斯药品有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4126817-A1 | SUBSTITUTED 5-HYDROXYINDOLE COMPOUNDS AS MODULATORS OF ALPHA-1 ANTITRYPSIN | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | MAPK14 4364/4885KDM1A 3218/4885RAB9A 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.